Tempus AI — AI-Driven Precision Medicine Platform Scaling Into a Large Diagnostics TAM

Tempus AI, Inc. is a precision-medicine technology company that combines genomic sequencing and molecular diagnostics with an AI-driven data and analytics platform. The company operates primarily in oncology, with expanding efforts in cardiology, neuropsychiatry, and infectious disease.

How it makes money:

• Genomics/testing revenue: Orders and performs molecular sequencing tests (tissue and liquid biopsy), generating per-test revenue reimbursed by payers or paid by providers/pharma.
• Data and services revenue: Licenses de-identified multimodal data to pharmaceutical and biotech companies for R&D, trial matching, and drug development; also provides AI-enabled clinical decision support and algorithmic tools to providers.

Customers: Health systems, oncology practices, academic medical centers, and pharmaceutical/biotech companies. Pharma partners are the primary customers for the high-margin data segment.

Scale: With a market cap of $11.6B and 175.39M shares outstanding, Tempus is a mid-cap in the diagnostics/health-tech space. The company remains unprofitable on a GAAP basis (EPS of -$1.44), reflecting heavy investment in sequencing infrastructure, R&D, and platform build-out. Public float of 115.90M shares represents roughly 66% of shares outstanding.

Near-term (next 12 months):

• Continued volume growth in oncology sequencing as reimbursement coverage broadens and ordering friction declines.
• New and expanded pharma data-licensing contracts, which are lumpy but high-margin and can move quarterly revenue meaningfully.
• Cross-selling AI decision-support tools into existing provider relationships, increasing revenue per account.

Medium-term (2–4 years):

• Expansion into non-oncology indications (cardiology, neuropsychiatry), each representing a new TAM with existing sequencing and data infrastructure leverage.
• International expansion, where comprehensive genomic profiling penetration is even lower than in the U.S.
• Increasing contribution of the data/AI segment to total revenue, which should lift consolidated gross margin and improve the path to profitability.

The key gating factors are reimbursement decisions, pharma R&D budget cycles, and the company's ability to absorb fixed costs as volume scales.

Narrative: The financial story hinges on mix shift. Sequencing revenue scales volume but carries lower gross margin and requires lab capacity investment. Data and services revenue is higher-margin and less capital-intensive. As the data segment grows as a share of the total, consolidated gross margin should expand, and operating leverage should begin to appear as fixed R&D and platform costs are spread over a larger revenue base. The -$1.44 EPS reflects the current cost structure; the question is how quickly revenue growth converts into margin expansion and narrowing losses. Cash position and burn rate are critical — a company at this stage with negative EPS may need to raise capital, which would dilute existing shareholders.

Market size/TAM: Precision medicine and comprehensive genomic profiling represent a multi-tens-of-billions U.S. TAM, with global expansion adding further runway. Adjacent data/AI-in-drug-development markets add a separate, high-margin layer.

Competitive positioning: Tempus's differentiation is the integrated data + AI layer on top of sequencing, not sequencing alone. This creates switching costs for providers and pharma partners once integrated into workflows, but it competes against both large diagnostics incumbents and specialized data players.

Named comparables:

• Guardant Health (GH): Liquid biopsy and comprehensive genomic profiling competitor, particularly in oncology.
• Natera (NTRA): Molecular diagnostics with strength in MRD and women's health; broader diagnostics comparison.
• Veracyte (VCYT): Genomic diagnostics with a focus on clinical utility and reimbursement.
• Exact Sciences (EXAS): Larger-scale diagnostics player, useful for scale and reimbursement benchmarking.

Tempus's data/AI monetization angle distinguishes it from pure-play diagnostics comparables, but it also means its valuation is more sensitive to data-segment execution than peers.

DCF discussion: A discounted cash flow approach is challenging here because the company is currently unprofitable with negative EPS (-$1.44), so near-term cash flows are negative and terminal value dominates the output. A DCF would require assumptions about (1) revenue growth trajectory, (2) gross margin expansion as data mix rises, (3) timing of EBITDA breakeven, and (4) a discount rate reflecting the 3.72 beta. Given the high beta and early-stage cash flow profile, the DCF is highly sensitive to terminal assumptions, and small changes in the discount rate or terminal growth produce wide valuation ranges. It is best used as a sanity check rather than a primary anchor.

Comparable multiples:

Given negative EPS, P/E is not meaningful for TEM. Valuation should be framed on EV/Revenue and EV/Gross Profit, with a premium justified only if the data/AI segment scales as expected. At $64.71 and an $11.6B market cap, the market is pricing substantial future data monetization — execution risk is embedded in the multiple.

• Profitability and cash burn: Negative EPS (-$1.44) means continued losses; if data revenue does not scale fast enough, the company may need to raise capital, diluting shareholders.
• Reimbursement risk: Payer coverage decisions and rate pressure directly affect sequencing revenue and margins.
• High beta and volatility: Beta of 3.72 means the stock can move dramatically on macro sentiment, independent of company fundamentals.
• Crowded short interest: 29.17% of float short cuts both ways — squeeze potential on good news, but amplified selling pressure on bad news.
• Competitive and regulatory risk: Large diagnostics incumbents and specialized data players compete for the same pharma and provider relationships; data privacy and diagnostic regulation could raise compliance costs.